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Abstract: The lack of appropriate human cardiomyocyte-based experimental platform has 
largely hindered the study of cardiac diseases and the development of therapeutic 
strategies. To date, somatic cells isolated from human subjects can be reprogramed into 
induced pluripotent stem cells (iPSCs) and subsequently differentiated into functional 
cardiomyocytes. This powerful reprogramming technology provides a novel in vitro human 
cell-based platform for the study of human hereditary cardiac disorders. The clinical 
potential of using iPSCs derived from patients with inherited cardiac disorders for 
therapeutic studies have been increasingly highlighted. In this review, the standard 
procedures for generating patient-specific iPSCs and the latest commonly used cardiac 
differentiation protocols will be outlined. Furthermore, the progress and limitations of 
current applications of iPSCs and iPSCs-derived cardiomyocytes in cell replacement 
therapy, disease modeling, drug-testing and toxicology studies will be discussed in detail. 
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1. Introduction 
Cardiomyocytes, or heart muscle cells, are fragile but important constituents of the myocardium.  
It is generally believed that humans are born with a fixed amount of cardiomyocytes; therefore, the 
death of these muscle cells may cause permanent damage to the heart. Recently, Bergmann and 
colleagues have evidenced a revolutionary notion of the in vivo regeneration and renewal of 
cardiomyocytes in humans [1]; nevertheless, the rate of cardiomyocyte turnover in their experiment 
appeared to be extremely slow. In fact, following myocardial injury, the heart usually repairs itself by 
cellular hypertrophy [2]. In case of a substantial loss of cardiomyocytes such as severe myocardial 
infarction, the damaged tissue is replaced with fibroblasts, rather than functional cardiomyocytes.  
To this end, the heart function is permanently impaired. Attempts of using adult stem cells or 
embryonic stem cells in replacing the damaged myocardium have been made, and several successful 
cases have been reported. Yet, such a replacement approach is impeded by various factors, for 
instance, the limiting sources of stem cells as well as the non-self rejection issues. In 2007, Yamanaka 
and colleagues demonstrated the first time that adult human fibroblasts could be reprogrammed into 
the pluripotent stem cells when supplemented with well-defined culturing factors [3]. Based on this 
revolutionary reprogramming approach, any fully differentiated cells obtained from patients should be 
theoretically able to be reprogrammed into induced pluripotent stem cells (iPSCs), and further 
differentiated into specialized cells of desired interest such as cardiac derivatives. The iPSCs obtained 
would be patient-specific; they not only provide a new source for regenerative medicine, but also offer 
a human cell based platform for the studies of modeling of inherited cardiac diseases and screening of 
potential cardiovascular drugs. In this review, the clinical potentials of patient-specific iPSCs in 
therapeutic treatments of cardiac disorders will be addressed in detail. 
2. Patient-Specific iPSCs and Their Cardiac Derivatives 
In 2006, Yamanaka and colleagues demonstrated for the first time that the exogenous expression of 
four transcription factors—Oct4, Klf-4, Sox-2 and c-Myc [4]—Initiated the reprogramming of 
terminally differentiated murine somatic cells (skin fibroblasts) into iPSCs, which were characterized 
with adequate pluripotency. Similar to embryonic stem cells, these iPSCs were able to self-renew, 
proliferate and differentiate into various cell types including neurons and cardiomyocytes [5,6].  
The same research group at a later time showed that human somatic cells could also be reprogrammed 
into iPSCs [3,7]. These technological breakthroughs have made substantial impacts in cell replacement 
therapy, disease modeling and therapeutic discovery sectors. Although the cells from a patient with 
myocardial infarction can be reprogrammed and differentiated into functional cardiomyocytes, the 
replacement of the defective cells of a particular patient is still theoretical. Nevertheless, iPSCs 
generated from patients with inherited cardiac diseases, following in vitro cardiac differentiation, are 
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still valuable tools for disease modeling and development of personalized medicine (Figure 1), as the 
iPSCs-derived cardiomyocytes possess the defective genes of the patients. 
Figure 1. The clinical applications of the cardiomyocytes derived from patient-specific iPSCs. 
 
3. Standard Procedures in Generating Patient-Specific iPSCs and Their Cardiac Derivatives 
In general, the generation of human iPSCs-derived cardiomyocytes involves three major steps:  
(i) collection of somatic tissues/cells; (ii) reprogramming; and (iii) cardiac differentiation. 
3.1. Collection of Somatic Tissues/Cells 
The protocol of Yamanaka and colleagues suggested the use of skin fibroblasts as the starting 
material of iPSCs generation. However, the invasive procedures of collecting skin biopsy actually 
caused many patients, especially pediatric subjects, to refuse donating tissue samples for iPSCs 
generation. In this regard, less invasive alternatives are obviously more preferable in clinical practices. 
It is now evidenced that apart from skin fibroblasts, many other cell types, such as hair follicle cells, 
peripheral blood cells as well as uro-epithelial cells, could also be reprogrammed into iPSCs [8–13]. 
Among these cells, the collection of uro-epithelial cells from urine accounts for the simplest and most 
convenient way. This non-invasive method eliminates pain or wound caused by skin biopsy collection; 
thus, is more likely to be accepted by patients. In fact, our laboratory is now routinely collecting urine 
samples from patients for iPSCs generation [14,15]. 
3.2. Reprogramming 
The first generation of reprogramming method involved the use of retrovirus vectors in infecting  
four transcription factors (Oct4, Klf4, Sox2 and c-Myc) into cultured fibroblasts. This method is quite 
robust; for this reason, many laboratories, including ours, are routinely using this method for iPSCs 
generation. However, the reprogramming efficiency of this method is not high (about 0.0002%). 
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Moreover, the use of retrovirus vectors is a big concern in clinical applications. Therefore, several 
alternative methods have been proposed. For example, Nanog and Lin28 are suggested as additional 
reprogramming factors in some protocols since the addition of these two factors increased the 
efficiency to about 0.05% for fetal fibroblasts [16]. As retrovirus only infects actively dividing cells, 
the use of lentivirus-based vectors may be a better option for the cell types that are non-actively 
dividing or less proliferative (e.g., cardiac fibroblasts). It is generally accepted that lentivirus-based 
vectors can transduce both dividing and non-dividing cells. On top of that, lentivirus-based vectors can 
accommodate much larger inserts. The four essential reprogramming factors Oct4, Klf4, Sox2 and  
c-Myc could be linked up within one single expression cassette [17] and simultaneously inserted into a 
single vector. This strategy eliminates the need for producing multiple transducing vectors; thus it 
avoids the possible stoichiometric and temporal interference among individual viruses [18]. 
Despite that retrovirus- and lentivirus-based vectors are widely used in iPSCs generation, the 
incorporation of viral sequences into the host genome is still an important concern in clinical 
applications, especially in the cell replacement therapy utilizing patient-specific iPSCs. For addressing 
this issue, the application of a Cre-loxP system in the lentivirus backbone has been suggested, so that 
the viral sequences could be eventually cleaved from the host genome upon the execution of  
Cre-recombinase [19,20]. Nevertheless, the use of non-integrative viruses appears to be a more 
acceptable method. For example, non-integrative viruses, such as adenovirus and Sendai virus, have 
been successfully used in some reprogramming protocols of human fibroblasts [21,22]. In addition, 
epigenetic reprogramming methods, such as transfection of mRNA, miRNA, minicircle vectors and 
episomal plasmids are regarded as the possible alternatives for footprint-free iPSCs reprogramming. 
3.3. Cardiac Differentiation 
In spontaneous differentiation, cardiomyocyte is one of the most easily identifiable cell types.  
Even in the absence of specific growth factors, spontaneous beating clusters could be observed when 
iPSCs are allowed to form aggregates (embryoid bodies) in a culturing suspension. However, the 
actual number of cardiomyocytes within a spontaneous beating embryoid body may comprise as low 
as merely 1% of the total cell population. It is obvious that spontaneous differentiation is not sufficient 
for the generation of iPSCs-derived cardiomyocytes in an adequate quantity for most experimental 
assays or applications. Early methods of directing cardiac differentiation involved the co-culture of 
iPSCs with END-2 endodermal cells. This END-2 co-culturing method has been used widely for 
cardiac differentiation of human embryonic stem cells and is relatively robust [23,24]. However, the 
difficulty in separating the cardiomyocytes from the feeder layers denotes a main drawback of this 
method. To date, many feeder-free cardiac differentiation protocols have been developed, so that 
problems associated with feeder layers can be eliminated. Most of these feeder-free methods involve 
the incubation with growth factors, such as the BMP4, Activin A, VEGF and DKK that regulate the 
pathways directing heart formation during fetal developments [6,25]. Recently, Palecek and colleagues 
reported a successful application of Wnt pathway inhibitors in directing cardiac differentiation of 
human iPSCs [26,27]. By modulating the Wnt/β-catenin signaling under fully defined conditions, 
monolayers of virtually pure cardiomyocytes (up to 98%) were obtained in merely 14 days. 
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4. Application of Patient-Specific iPSCs in Cell Replacement Therapy/Regenerative Medicine 
Increasing evidences showed that the adult human heart possesses a certain degree of regenerating 
power. Following severe cardiac injury, cardiac hypertrophy and scarring are indeed the major 
repairing mechanisms to maintain minimum cardiac functions and prevent further damages. However, 
without the replacement of new cardiomyocytes, the ordinary repairing mechanisms usually result in 
the continual increase of cardiac workload that further worsens the injured condition and even leads to 
chronic heart failure of the patient. To this end, various studies have been converged on the use of 
pluripotent stem cells in cardiac recovery. 
A previous study reported that the transplantation of human embryonic stem cells-derived 
cardiomyocytes into the infarcted myocardium of an immunodeficient rodent partially remuscularized 
myocardial infarcts and improved cardiac function [28,29]. At a later stage, Gaballa and colleagues 
demonstrated that cell sheets composed of rat or human cardiac progenitor cells, when transplanted 
into the infarcted heart, could proliferate and differentiate into functional cardiomyocytes, and rescue 
myocardial function [30]. 
Besides human embryonic stem cells, human iPSCs also possess the ability to differentiate into 
cardiac lineages. Since iPSCs can be derived from any individual, the use of human iPSCs in 
regenerative medicine can avoid the ethical issues arising from the use of embryonic materials. 
Furthermore, iPSCs can be produced from the same individual who is receiving the cell replacement 
therapy, so that immunological incompatibility should become less significant. 
Recently, Watt and colleagues attempted to investigate the potential benefits of human  
iPSCs-derived progenitors. In their study, human iPSCs-derived cardiac progenitor cells were injected 
into the pre-infarct hearts of rats. The injected cells were able to differentiate into cardiomyocytes and 
smooth muscle fibers, and were retained in the rat hearts for at least 10 weeks after myocardial 
infarction. When comparing to the control group, the animals that received human-iPSCs-derived 
cardiac progenitor cells showed some improvement in the left ventricular ejection fraction [31]. 
It should be noted that although many studies have pointed out the beneficial effects of human 
embryonic stem cells and iPSCs against ischemic cardiac injuries, most of the studies only involved a 
relatively short follow-up period (see Table 1); thus, the long term efficacy of iPSCs-derived cardiac 
progenitors remains questionable. 
Table 1. Examples of using iPSCs in cell replacement therapies. 
Cell Type 
Animal 
Model 
Number of 
Cell 
Delivery 
Method 
Timing of the 
Delivery 
Follow up 
Duration 
Reference
iPSC Mouse 50,000 IM 
Immediately after MI 
induction 
2 weeks [30] 
iPSC-derived 
cardiac 
progenitors 
Rat 2 × 106 IM 
10 min after MI 
induction 
10 weeks [31] 
Cardiosphere Rat - Cell sheet 
Immediately after MI 
induction 
3 weeks [32] 
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5. Applications of iPSCs-Derived Cardiomyocytes in Modeling Genetic Cardiomyopathies 
Cardiomyopathies are heterogeneous groups of diseases of cardiomyocytes. Pathologically, the 
diseases could be caused by non-genetic factors such as viral infection though genetic contributions are 
frequently observed [33]. To date, over 50 genes have been reported to be associated with various 
forms of cardiomyopathies; yet, the studies of the pathogenic mechanisms underlying specific genetic 
defects remain elusive due to the lack of appropriate experimental models. 
Theoretically, the affected tissues obtained from patients with cardiomyopathies are the best options 
for pathophysiological studies; however, for cardiac diseases, the limitation in obtaining and 
maintaining cardiac biopsy samples highly hindered this strategy. 
To compensate this limitation, transgenic animals are commonly used for modeling human genetic 
defects. Nonetheless, due to the substantial physiological differences between the hearts of human and 
those of mice [34–36], the use of transgenic mouse lines in modeling human genetic cardiomyopathies 
is of little practical value. For example, in terms of ion-channel physiology, transgenic mouse models, 
in most cases, only partly recapitulate the disease phenotypes [36,37]. The phenotypic differences 
between species accentuate the importance of a novel human cardiomyocyte-based model in the 
studies of heritable cardiac defects, and the cardiomyocytes derived from patient-specific iPSCs should 
be one of the most desirable options. 
In general, if the mutation of the gene of interest does not interfere in cardiac differentiation, 
cardiomyocytes can be continually generated from patient-specific iPSCs. This continuous supply of 
cardiomyocytes indeed resembles the cardiac biopsy samples that could hardly be obtained from 
patients with specific inherited cardiac defects; thus these patient-specific iPSCs-derived 
cardiomyocytes provide a convenient and valuable platform for research purposes. In fact, various 
recent reports have demonstrated that the cardiomyocytes derived from patient-specific iPSCs were 
able to recapitulate disease phenotypes of various types of Long QT syndromes [38–40]. These data 
clearly evidenced the feasibility of utilizing the patient-specific iPSCs-derived cardiomyocytes in 
modeling heritable cardiomyopathies. 
In 2010, Laugwitz and colleagues established the first patient-specific iPSCs based model for type 1 
Long QT syndrome [41]. In their study, the skin fibroblasts from patients carrying an autosomal 
dominant missense mutation (R190Q) in the KCNQ1 gene were effectively reprogrammed into iPSCs. 
The resultant iPSCs were further differentiated into atrial- and ventricular-like cardiomyocytes and 
subjected to patch-clamp analysis. When comparing to the control, the iPSCs-derived cardiomyocytes 
with the KCNQ1 mutation showed a markedly prolonged duration of action potential, altered 
activation and deactivation properties of IKs, and an abnormal response to catecholamine stimulation. 
Immunostaining analysis demonstrated the failure of mutated Kv7.1 potassium channel protein in its 
trafficking to the plasma membrane; this finding may provide an explanation to the cellular pathogenic 
mechanism of the KCNQ1R190Q mutation. Undoubtedly, the use of iPSCs-derived cardiomyocytes in 
modeling inherited cardiac disorders is feasible. 
In addition to Long QT syndromes, cardiomyocytes derived from patient-specific iPSCs have also 
been used in the modeling of some other genetic cardiac disorders (Table 2); examples are outlined  
as follows:  
J. Clin. Med. 2014, 3 1111 
 
 
Table 2. Examples of using iPSCs-derived cardiomyocytes for modeling genetic cardiomyopathies. 
Disorder Gene Involved Details of the Mutation References
Long QT syndrome, Type 1 KCNQ1 missense mutation (R190Q) leads to the production of a mutant protein [41] 
Long QT syndrome, Type 2 KCNH2 missense mutation (A614V) leads to the production of a mutant protein [38] 
Long QT syndrome, Type 2 KCNH2 missense mutation (G1618A) leads to the production of a mutant protein [40] 
Long QT syndrome, Type 2 KCNH2 missense mutation (R176W) leads to the production of mutant protein [42] 
Long QT syndrome, Type 3 SCN5A 
Multiple mutations (G5287A; V1763M) leads the production of a 
mutant protein 
[43] 
Long QT syndrome, Type 8 CACNA1C Missense mutation (G406R) leads to the production of a mutant protein [44] 
Catecholaminergic 
polymorphic ventricular 
tachycardia, Type 1 
RYR2 
Missense mutation (F2483I) leads to the production of a mutant protein 
with an altered FKBP12.6 binding domain 
[45] 
Catecholaminergic 
polymorphic ventricular 
tachycardia, Type 1 
RYR2 Missense mutation (S406L) leads to the production of a mutant protein [46] 
Catecholaminergic 
polymorphic ventricular 
tachycardia, Type 2 
CASQ2 Missense mutation (D307H) leads to the production of a mutant protein [47] 
Catecholaminergic 
polymorphic ventricular 
tachycardia, Type 2 
CASQ2 Missense mutation (D307H) leads to the production of a mutant protein [47] 
Dilated cardiomyopathy TNNT2 missense mutation (R173W) leads to the production of a mutant protein [48] 
Dilated cardiomyopathy DES missense mutation (A285V) leads to the production of a mutant protein [49] 
Hypertrophic 
cardiomyopathy 
MYH7 Missense mutation (R663H) leads to the production of a mutant protein [50] 
Friedreich ataxia-associated 
hypertrophic 
cardiomyopathy 
FXN 
GAA repeat expansion in the first intron leads to the partial silencing 
of gene expression 
[51] 
5.1. Modeling Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) 
Although inherited arrhythmogenic disorders are frequently associated with the mutations in the genes 
encoding the ion channel components, a special kind of inherited ventricular arrhythmia called 
catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by the mutations in genes 
encoding the proteins mediating intracellular calcium transient. In response to emotional or physical stress, 
CPVT patients may manifest ventricular premature beats and bidirectional or polymorphic ventricular 
tachycardia, which leads to episodic syncope, seizures and sudden death [52,53]. So far, two types of 
CPVT have been described based on their difference in the mode of inheritance. The autosomal 
dominant form that accounts for up to 50% of the cases has been linked to the mutations in the RYR2 
gene that encodes the cardiac ryanodine receptor [54], while a rare autosomal recessive form results 
from the mutations in the CASQ2 gene that encodes the cardiac calsequestrin [55]. Functionally, 
ryanodine receptor and calsequestrin work together to mediate the release of calcium ions from the 
sarcoplasmic reticulum (SR) in the cardiac muscles during excitation-contraction coupling. As such, it 
is not surprising that mutations in the RYR2 and CASQ2 genes that result in functional derangements in 
intracellular calcium handling may result in arrhythmia. Since 2004, the pathophysiological roles of 
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various RYR2 and CASQ2 mutations in driving the development of CPVT have been investigated in 
several transgenic animal or cell models [56–59]. Although most of the models were able to 
recapitulate the major CPVT phenotypes, such as SR calcium leak and catecholamine-induced delayed 
after-polarizations (DADs), the clinical significance of these models were limited by the substantial 
difference in the cardiac electrophysiology between rodents and human. Addressing this issue, the 
pathogenic effects of various CPVT associated mutations have been studied in patient-specific iPSCs 
models. These include the RYR2F24831I, RYR2S406L, CASQ2D307H mutations [45–47]. Similar to the rodent 
models, all these iPSCs-based models were able to recapitulate the CPVT phenotypes, and the results 
confirmed that the diastolic SR calcium leak contributes to generation of DADs [45–47]. Except for disease 
modeling, the iPSCs-based CPVT models also provided a human cardiomyocytes-based platform for drug 
testing and toxicology studies. For example, in a recent report, Laugwitz and colleagues demonstrated that 
dantrolene ameliorates the CPVT phenotypes caused by RYR2S406L mutation using the cardiomyocytes 
differentiated from the CPVT patient-specific iPSCs [46]. So far, only limited therapeutics, such as  
beta-blockers, are being used for treating CPVT. It is anticipated that the success in generating the 
CPVT-specific iPSCs may help facilitate the development of novel therapeutic approaches in  
treating CPVT. 
5.2. Modeling Dilated Cardiomyopathy Associated with TNNT2 Mutation 
Dilated cardiomyopathy (DCM) is the most common subtype of cardiomyopathy, and is characterized 
by the abnormal enlargement of ventricles, thinning of ventricular walls and the marked systolic 
dysfunction [33]. It has been estimated that about 50% of the cases are of genetic causes [60–63].  
The pathological mechanisms associated with TNNT2 gene mutations have been evaluated in a 
transgenic mouse model, in which the null mutation of this gene denoted an impaired contractile 
function of the heart [64,65]. Yet, how the specific TNNT2 mutation contributes to the development of 
DCM phenotype in human remains ambiguous. 
In 2012, Wu and colleagues generated iPSCs from DCM patients carrying a disease associated- 
mutation in the gene encoding cardiac troponin-T (TNNT2) [48]. Sequencing analysis showed that 
such mutation causes the 173rd amino acid residue of the cardiac troponin-T to change from an 
arginine (R) to a tryptophan (W). Clinically, patients with this mutation develop the typical DCM 
symptoms including left ventricle dilation and reduced ejection fraction. Skin biopsy samples were 
collected from affected and normal individuals of three generations of a single family for iPSCs 
generation. The resultant iPSCs were then differentiated into cardiomyocytes for functional analyses. 
When comparing to the control, the cardiomyocytes derived from the mutation containing-iPSCs 
showed abnormal sarcomeric alpha-actinin distribution. Functionally, the mutant cardiomyocytes 
exhibited impairments in contractility and reduction in calcium handling ability upon β-adrenergic 
stimulation. These observations indicated that the increased susceptibility to inotropic stress may be a 
signature characteristic of the TNNT2R173W mutation in DCM development. 
5.3. Modeling Cardiomyopathy Associated with DES Mutation 
The DES gene encodes the intermediate filament protein desmin, but the exact function of desmin is not 
well defined. Nevertheless, mutations in the DES gene are commonly observed in DCM patients [66]. 
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Phenotypically, mutations leading to the loss of DES gene function usually give rise to a significant 
accumulation of desmin-positive aggregates in the cardiomyocytes of affected individuals. 
Lately, by utilizing the whole-exome sequencing approach, our laboratory has identified a novel DES 
mutation in a patient with left ventricular dilation and impaired left ventricular ejection function [49].  
In this DES mutation, we recognized a change of the alanine (A) residue to valine (V) at the 285th 
amino acid position. In the transgenic mouse model with complete desmin deficiency, phenotypes such 
as hypertrophic and dilated cardiomyopathy [67] were observed. Surprisingly, the patient with 
DESA285V mutation produced a mutant desmin possessing molecular weight and immunoreactivity 
comparable to the wild type desmin protein. To investigate the pathological significance of this novel 
DES mutation, we have generated skin fibroblasts-derived iPSCs from this DESA285V patient.  
These DESA285V iPSCs were subsequently differentiated into cardiomyocytes for structural and 
functional studies. When compared to the normal cardiomyocytes, the ones carrying the DES mutation 
exhibited abnormal protein aggregations in sarcomere and Z-disc streaming. In addition, contraction 
arrest was observed in the mutant cardiomyocytes upon isoproterenol stimulation. These observations 
not only provided an explanation to the pathogenic mechanism underlying the DESA285V mutation, but 
also validated the causal ion relationship between the DES mutation and the DCM phenotype observed 
in that patient [49]. 
5.4. Modeling Hypertrophic Cardiomyopathy Associated with MYH7 Mutation 
Hypertrophic cardiomyopathy (HCM) is a heritable cardiac disorder characterized by the abnormal 
left ventricular thickening and diastolic dysfunction in the absence of an identifiable hemodynamic  
cause [68]. About 13 HCM-associated genes have been identified to date and most of them encode 
sarcomeric proteins [69]. Transgenic mouse and rabbit models have been established for studying the 
pathological mechanisms of HCM [70–72]; however, the mechanistic roles of altered contractile 
function in the development of HCM remain inconclusive. Very recently, Lan and colleagues 
generated an iPSCs-line from patients carrying one HCM-associated mutation in the MYH7 gene.  
In their case, the 663rd residue of the β-myosin heavy chain is changed from an arginine to a histidine 
as a result of a missense mutation. The patient-specific iPSCs were differentiated into cardiomyocytes 
for functional analyses. The mutant-containing cardiomyocytes recapitulated the key features of HCM, 
including increased cell size and arrhythmia. The intracellular calcium transient profile indicated that 
the diseased cardiomyocytes showed a significant increase in the resting intracellular calcium level 
when comparing to the normal cardiac muscle fibers. Interestingly, pharmaceutical inhibition of 
calcium entry helped to prevent the development of HCM phenotypes in the mutant cardiomyocytes 
suggesting the MYH7 mutation altered the calcium homeostasis dysfunction [50]. 
5.5. Modeling Friedreich Ataxia Associated Cardiomyopathy 
Apart from sarcomeric proteins, abnormality in the mitochondrial proteins may also contribute to 
HCM development. For example, deficiency in the mitochondrial protein frataxin may lead to Friederich 
ataxia (FRDA), in which patients usually develop with HCM phenotype to varying degrees [73].  
In FRDA, abnormal expansions of the GAA repeat within the first intron of the FXN gene may result 
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in the silencing of the gene, which in turn reduces or completely abolishes the production of the  
frataxin protein. 
Frataxin has been implicated in the mechanism of iron-sulfur cluster biosynthesis; however, the 
contribution of frataxin-deficiency to cardiomyopathy development has yet to be elucidated. 
To test whether iron homeostasis deregulation accelerates the reduction in energy synthesis 
dynamics that contributes to impaired cardiac calcium homeostasis and contractile force, we have 
recently generated skin fibroblasts-derived iPSCs from a FRDA patient [51]. The FXN gene expression 
in that patient was endogenously silenced. Phenotypically, the FRDA iPSCs-derived cardiomyocytes 
exhibited a disorganization of the mitochondrial network complemented with mitochondrial DNA 
depletion. Consistent with the mitochondrial disorganization, the energy synthesis dynamics, in terms 
of ATP production rate, in the diseased cardiomyocytes was impaired. Interestingly, when the diseased 
cardiomyocytes were subjected to iron overloading, a significant impairment in the calcium handling 
property was observed. These results indicated that patient-specific iPSCs are useful tools for studying 
FRDA-associated cardiac defects. 
6. Application of Patient-Specific iPSCs-Derived Cardiomyocytes in Efficacy Testing and  
Drug Screening 
Owing to the limited sources of human cardiomyocytes for in vitro analyses, the effects of a 
putative cardiac drug have to be conventionally tested in the well-established rabbit or canine Purkinje 
fiber model before proceeding to clinical trials. Nevertheless, as the non-human based cellular models 
often give false-positive or inconsistent results [74–76], many drugs that have passed the animal tests 
ended up with failure in the clinical trials. Recent reports demonstrated that human embryonic stem  
cells-derived cardiomyocytes exhibited excellent pharmacological response to various known 
antiarrhythmic agents; thus they may be a potential alternative to animal cardiomyocytes [77,78]. 
However, due to the difference in genetic background, individuals with similar cardiac disorders could 
show quite different responses towards a particular drug. In this regard, the patient-specific  
iPSC-derived cardiomyocytes offer an exclusive platform for evaluating the efficacy of a particular 
drug or treatment strategy on a personal basis. 
Based on the latest breakthrough in the cardiac differentiation protocol, a yield of more than 80% in 
cardiomyocyte differentiation has been achieved [27]. When these patient-specific iPSCs-derived 
cardiomyocytes are applied to a high throughput assay platform, such as multielectrode arrays analysis, 
the effects of a testing drug on cellular electrophysiology can be evaluated in a short period of time. 
Emerging evidences from our group and other investigators have pointed out that altered calcium 
handling could be an important pathogenic mechanism underlying cardiomyopathies [48,49,79,80]; 
drugs that affect calcium homeostasis should be of great therapeutic potential. Mercola and colleagues 
have recently developed a high throughput automated kinetic image cytometry system for the 
measurement of calcium ion dynamics. This system enabled the authors to simultaneously measure 
individual calcium transients from 100 human iPSCs-derived cardiomyocytes [81]. Taking advantage 
of such system, high throughput screenings of calcium handling-enhancing properties of known or 
novel drugs can be performed on patient-specific iPSCs-derived cardiomyocytes. 
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7. Application of Patient-Specific iPSCs-Derived Cardiomyocytes in Toxicology Test 
In addition to pharmacological studies, the cardiomyocytes derived from iPSCs are of great 
potential in the toxicology tests. So far, isolated canine cardiomyocytes are the most popular  
pre-clinical model for cardiac safety testing of a developing drug. However, as mentioned in the last 
section, the reliability of such model remains questionable. As a matter of fact, many drugs that have 
passed the animal tests turned out to show unanticipated cardiac toxicity when administered to  
patients [82], thus, a more predictive and reliable human cardiomyocyte-based model for toxicology test is 
of immediate demand. Increasing evidences suggested that the pharmacological sensitivities of human 
ESCs and iPSCs-derived cardiomyocytes are much more advanced than any animal models [77,78], and 
they should be good detectors for any undesired proarrhythmic side effects of a developing drug. 
Recently, Mendenius and colleagues proposed the possibility of using human ESCs and  
iPSCs-derived cardiomyocytes in the evaluation of drug-induced cardiac injury [83,84]. In their 
studies, the human ESCs- and iPSCs-derived cardiomyocytes were treated with doxorubicin, and the 
release of cardiac troponin T in culture medium was measured utilizing a Biocore-based system for the 
degree of cell injury. Compared to the conventional ELISA based assay, the surface plasmon 
resonance-based method not only provides superior sensitivity and specificity, but also allows 
simultaneous analysis of multiple samples. Consequently, the use of iPSCs-derived cardiomyocytes in 
toxicity predication appears to be feasible. 
8. Limitations of iPSCs 
The recent achievement in the patient-specific iPSC technology has created a new platform for 
regenerative medicine, disease modeling and personalized medication development. Yet, like many 
other technologies, the clinical applications of patient-specific iPSCs-derived cardiomyocytes are also 
hindered by various limitations. Though the latest advancement in cardiac differentiation protocol 
allows efficient generation of cardiomyocytes in a high yield, the human iPSCs-derived 
cardiomyocytes are actually less mature in terms of calcium homeostasis when compared to the human 
ESCs-derived cardiomyocytes as demonstrated earlier by our laboratory [85]. In other words, the 
patient-specific iPSCs-derived cardiomyocytes may not be suitable for modeling cardiac defects 
resulted from mutations of genes that regulate calcium transients, such as the mutations in the gene 
encoding the phospholamban. 
Furthermore, it should be noted that a high yield of cardiac differentiation is not equivalent to high 
purity. In fact, iPSCs-derived cardiomyocytes are always grown in a mixed population of atrial, 
ventricular and nodal subtypes. These subtypes do possess different electrophysiology properties.  
So far, most transplantation studies were performed in rodent models [28,29]. As rodents have a much 
faster heart rate compared to humans, the injection of human cardiomyocytes into rodent hearts may 
not create significant arrhythmia problems. However, the injection of mismatched subtypes of 
cardiomyocytes into a patient’s heart may lead to a medical emergency. Unfortunately, no efficient 
way is available to sort the subtypes of iPSCs-derived cardiomyocytes into pure populations.  
The direct application of patient-specific iPSCs cardiomyocytes in regenerative medicine, therefore, 
remains a theoretic foundation. Besides the issue of mixed subtypes, the immature phenotype of 
J. Clin. Med. 2014, 3 1116 
 
 
iPSCs-derived cardiomyocytes also limits its application in drug screening experiments. To this end, it 
is important to verify and validate the results obtained in the initial screening steps. 
9. Conclusions 
The cardiomyocytes derived from patients-specific iPSCs are of great potential in many clinical 
applications. This authentic human cardiomyocyte-based system is expected to compensate for the 
limitations of the current experimental animal models. This review provides detailed descriptions in 
the strategies and workflow of using the patient-specific iPSCs-derived cardiomyocytes in regenerative 
medicine, disease modeling and pharmacological applications. The examples illustrated in this review 
clearly evidenced the practical values of this novel technology. However, various limitations, such as 
the immaturities of iPSCs-derived cardiomyocytes, still need to be addressed, and future studies 
resolving these issues would be beneficial to the use of patient-specific iPSCs in clinical applications. 
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